CDT Equity Inc. (CDT)
Data as of , from SEC Form 4 filings.
See up to 3 months of CDT. The 7-day demo opens the 1M and 3M ranges and puts CDT on your watchlist.
Start 7-day demoLatest CDT insider trades
Andrew Regan - OfficerOpen-market sale290 sh
Mark Andrew Taylor - 10% OwnerOpen-market sale$4K
About CDT Equity Inc. (CDT)
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
- NAPLES, FL
- 4
- 2023
- XNAS
CDT Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 290 | - |
| Other acquisition / disposition | 3 | 16,310,490 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CDT insider transactions (Form 4)
4322 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Andrew Regan - Officer | Other | Common Stock | 5,436,830 footnote F1,F2 | - footnote F1,F2 | - | |
| Andrew Regan - Officer | Open-market sale | Common Stock | 290 footnote F1,F2,F6 | - footnote F1,F2 | - | |
| Andrew Regan - Officer | Other | Pre-Funded Warrants | 5,436,830 footnote F1,F2,F3 | $0.00 | $544 | |
| Andrew Regan - Officer | Other | Pre-Funded Warrants | 5,436,830 footnote F1,F2,F3 | $0.00 | $544 | |
| ||||||
| Mark Andrew Taylor - 10% Owner | Open-market sale | Common Stock | 5,000 footnote F1 | $0.75 footnote F4 | $4K | |
| Mark Andrew Taylor - 10% Owner | Open-market sale | Common Stock | 593,289 footnote F1 | $1.40 footnote F4,F5 | $829K | |
| Mark Andrew Taylor - 10% Owner | Open-market sale | Common Stock | 5,000 footnote F1 | $0.71 footnote F2 | $4K | |
| Mark Andrew Taylor - 10% Owner | Open-market sale | Common Stock | 1,464,711 footnote F1 | $1.44 footnote F2 | $2.11M | |
| ||||||
| Andrew Regan - Officer | Grant or award | Common Stock | 147,401 footnote F1,F2 | - footnote F2 | - | |
| Andrew Regan - Officer | Grant or award | Common Stock | 100,000 footnote F4 | $1.90 footnote F4 | $190K | |
| Andrew Regan - Officer | Other | Pre-Funded Warrants | 147,401 footnote F1,F2 | $0.63 | $15 | |
| ||||||
| Mark Andrew Taylor - 10% Owner | Other | Common Stock | 46,902 footnote F1,F2 | $0.00 footnote F1 | - | |
| Mark Andrew Taylor - 10% Owner | Other | Common Stock | 51,420,358 footnote F2,F3 | $0.00 footnote F3 | - | |
| Mark Andrew Taylor - 10% Owner | Other | Pre-Funded Warrants | 9,968,931 footnote F1 | $0.00 footnote F1 | - | |
| Mark Andrew Taylor - 10% Owner | Other | Pre-Funded Warrants | 51,161,318 footnote F1,F3 | $0.00 footnote F3 | - | |
| ||||||
 Chele Chiavacci Farley - Director | Grant or award | Common Stock | 10,553 footnote F1 | $6,500.00 | $11K | |
| Chele Chiavacci Farley - Director | Grant or award | Pre-Funded Warrants | 1,940,804 | $1.04 footnote F1 | $2.02M | |
| ||||||
| Andrew Regan - Officer | Grant or award | Common Stock | 224,800 | $11,187.50 | $402K | |
| Andrew Regan - Officer | Grant or award | Pre-Funded Warrants | 3,685,815 | $0.63 | $369 | |
| Andrew Regan - Officer | Grant or award | Common Stock | 1,120,000 | $34,315.00 | $769K | |
 James Bligh - Officer | Grant or award | Common Stock | 480,000 | $0.00 | - | |
 Simon Jeremy Fry - Director | Grant or award | Common Stock | 35,000 | $0.00 | - | |
| Simon Jeremy Fry - Director | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Chele Chiavacci Farley - Director | Grant or award | Common Stock | 35,000 | $0.00 | - | |
| Chele Chiavacci Farley - Director | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Freda C. Lewis-Hall - Director | Grant or award | Common Stock | 35,000 | $0.00 | - | |
| Freda C. Lewis-Hall - Director | Grant or award | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Chele Chiavacci Farley - Director | Grant or award | Stock Option (Right to Buy) | 420,000 | $5,325,000.00 | $30K | |
| Simon Jeremy Fry - Director | Grant or award | Stock Option (Right to Buy) | 420,000 | $5,325,000.00 | $30K | |
| Faith L. Charles - Director | Grant or award | Stock Option (Right to Buy) | 420,000 | $5,325,000.00 | $30K | |
| Freda C. Lewis-Hall - Director | Grant or award | Stock Option (Right to Buy) | 420,000 | $5,325,000.00 | $30K | |
| David Tapolczay - Officer | Grant or award | Stock Option (Right to Buy) | 840,000 | $6,892,500.00 | $77K | |
| James Bligh - Officer | Grant or award | Stock Option (Right to Buy) | 1,890,000 | $6,892,500.00 | $174K | |
| Chele Chiavacci Farley - Director | Grant or award | Common Stock | 299,238 | $6,892,500.00 | $27K | |
| Faith L. Charles - Director | Grant or award | Common Stock | 75,000 | - | - | |
| Faith L. Charles - Director | Grant or award | Common Stock | 266,594 | $6,892,500.00 | $24K | |
| Freda C. Lewis-Hall - Director | Grant or award | Common Stock | 437,976 | $6,892,500.00 | $40K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 1,500,000 | $7,822,500.00 | $156K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 1,368,991 | $7,695,000.00 | $140K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 939,009 | $7,710,000.00 | $97K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 1,016,823 | $9,000,000.00 | $122K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 1,250,000 | $8,482,500.00 | $141K | |
| Nirland Ltd - 10% Owner | Open-market sale | Common Stock, par value $0.0001 per share | 333,177 | $7,710,000.00 | $34K | |
Item 1.01, 2.03, 3.02, 9.01
Item 3.03, 5.03, 7.01, 9.01
Item 1.01, 2.03, 3.02, 9.01
Item 1.01, 2.03, 3.02, 9.01
CDT insider trading FAQ
What is the latest insider trade for CDT?
CDT Equity Inc. (CDT) had 1 insider filing in the last 90 days, with the most recent on 2026-09-02. The full record for CDT runs to 22 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CDT stock?
No insider purchases of CDT were filed in the last 90 days.
How many insiders are selling CDT stock?
1 insider sale of CDT was filed in the last 90 days.
Where can I see CDT SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CDT Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Andrew Regan view on EDGAR
- - Mark Andrew Taylor view on EDGAR
- - Andrew Regan view on EDGAR
- - Mark Andrew Taylor view on EDGAR
- - Chele Chiavacci Farley view on EDGAR
- - Andrew Regan view on EDGAR
- - Andrew Regan view on EDGAR
- - James Bligh view on EDGAR
- - Simon Jeremy Fry view on EDGAR
- - Chele Chiavacci Farley
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Insider activity in Health Care
- Where CDT's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CDT with a 7-day demo
- CDT on your watchlist
- Every CDT Form 4 filing on record
- Up to 3 months of CDT price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
